Protara Therapeutics, Inc.

NASDAQ:TARA

Biotechnology

Healthcare
$2.34 -1.27%

-$0.05 today

Market cap
$144.07M
Beta
1.45
P/E (TTM)
-2.7
EPS (TTM)
-$1.48
52W Low $2.77High $7.82

Volume 1.15M

Average 0.73M

TARA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Protara Therapeutics, Inc.NASDAQ: TARA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$90K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$90K.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$90K or moves back toward the trailing-twelve-month quarterly average of -$22.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$90K— QoQ
Last fiscal yearDec 2025
-$362K— YoY
LTMMar 2026
-$90K— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(362K) USD
Year-over-year change
—

Gross Profit vs competitors

How TARA compares with its peers on the latest reported figures

  • TARA's LTM Mar 2026 gross profit of -$90K is the lowest of the 10 companies compared; the peer median is $16.33M.
TARA Competitors Peer median
Gross Profit for TARA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CDXSCodexis, Inc.LTM Mar 2026$65.55M +83.9%-15.3%83.9%
IVVDInvivyd, Inc.LTM Mar 2026$51.41M +50.2%—92.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$34.56M -45.8%-31.5%100.0%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.49M +1115.8%+118.1%99.3%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.33M +133.3%—97.7%
OABIOmniAb, Inc.LTM Mar 2026$10.25M -61.7%—35.5%
MDWDMediWound Ltd.LTM Mar 2026$2.84M +2.7%-37.2%19.6%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 ———
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026-$31.98K ———
TARAProtara Therapeutics, Inc.LTM Mar 2026-$90K ———
Peer median (excluding TARA) $16.33M+50.2%-23.4%92.0%

Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00341K0362K
Gross Profit00(341K)0(362K)
Gross Margin—————
Research & Development21.09M16.81M24.79M31.7M42.63M
Selling, General & Admin26.4M20.74M18.62M17.45M21.92M
Operating Expenses47.49M67.06M43.27M49.15M64.19M
Depreciation & Amortization117K248K341K332K362K
EBITDA(45.4M)(64.57M)(40.08M)(44.26M)(57.08M)
EBITDA Margin—————
Operating Income(47.49M)(67.06M)(43.61M)(49.15M)(64.55M)
Operating Margin—————
Interest Income237K1.11M2.73M4.14M6.33M
Interest Expense1.74M1.14M000
Other Income / Expenses237K1.11M3.19M4.56M7.11M
Income Before Tax(47.25M)(65.95M)(40.42M)(44.6M)(57.44M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(47.25M)(65.95M)(40.42M)(44.6M)(57.44M)
Net Margin—————
EPS (Basic)(4.20)(5.86)(3.57)(2.17)(1.34)
EPS (Diluted)(4.20)(5.86)(3.57)(2.17)(1.34)
Weighted Avg Shares11.23M11.26M11.33M20.59M42.84M
Weighted Avg Shares (Diluted)11.23M11.26M11.33M20.59M42.84M

Protara Therapeutics, Inc.

NASDAQ:TARA

Intrinsic Alpha fair value

Locked

Current Price

$2.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.